309
Views
22
CrossRef citations to date
0
Altmetric
Clinical Features - Original Research

Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status

, , , , , , & show all
Pages 442-447 | Received 12 Dec 2017, Accepted 20 Apr 2018, Published online: 10 May 2018

References

  • Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271–276.
  • Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364:533–544.
  • Lin MT, Sun LC, Wu ET, et al. Acute and late coronary outcomes in 1073 patients with Kawasaki disease with and without intravenous γ-immunoglobulin therapy. Arch Dis Child. 2015;100:542–547.
  • Harnden A, Takahashi M, Burgner D. Kawasaki disease. Bmj. 2009;338:b1514.
  • Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr. 2004;16:508–514.
  • Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results from the nationwide survey in 2005-2006. J Epidemiol. 2008;18:167–172.
  • Eleftheriou D, Levin M, Shingadia D, et al. Management of Kawasaki disease. Arch Dis Child. 2014;99:74–83.
  • JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)–digest version. Circ J. 2010;74:1989–2020.
  • Newburger JW, Takahashi M, Gerber MA, et al. Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747–2771.
  • Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633–1639.
  • Ho CL, Fu YC, Lin MC, et al. Early immunoglobulin therapy and outcomes in Kawasaki disease: a nationwide cohort study. Medicine (Baltimore). 2015;94:e1544.
  • Muta H, Ishii M, Yashiro M, et al. Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics. 2012;129:e291–297.
  • Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2:1055–1058.
  • Zhang T, Yanagawa H, Oki I, et al. Factors related to cardiac sequelae of Kawasaki disease. Eur J Pediatr. 1999;158:694–697.
  • Yanagawa H, Tuohong Z, Oki I, et al. Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease. Pediatr Cardiol. 1999;20:248–251.
  • Maggio MC, Corsello G, Prinzi E, et al. Kawasaki disease in Sicily: clinical description and markers of disease severity. Ital J Pediatr. 2016;42:92–97.
  • Anderson MS, Todd JK, Glodé MP. Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. Pediatrics. 2005;115:e428–433.
  • Minich LL, Sleeper LA, Atz AM, et al. Pediatric Heart Network Investigators. Delayed diagnosis of Kawasaki disease: what are the risk factors? Pediatrics. 2007;120:e1434–1440.
  • Wilder MS, Palinkas LA, Kao AS, et al. Delayed diagnosis by physicians contributes to the development of coronary artery aneurysms in children with Kawasaki syndrome. Pediatr Infect Dis J. 2007;26:256–260.
  • Juan CC, Hwang B, Lee PC, et al. The clinical manifestations and risk factors of a delayed diagnosis of Kawasaki disease. J Chin Med Assoc. 2007;70:374–379.
  • Du ZD, Di Z, Du JB, et al. Comparison of efficacy among early, conventional and late intravenous gamma globulin treatment of Kawasaki disease. Zhonghua Yi Xue Za Zhi. 2009;89:1841–1843.
  • Sittiwangkul R, Pongprot Y, Silvilairat S, et al. Delayed diagnosis of Kawasaki disease: risk factors and outcome of treatment. Ann Trop Paediatr. 2011;31:109–114.
  • Bal AK, Prasad D, Umali Pamintuan MA, et al. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease. Pediatr Neonatol. 2014;55:387–392.
  • Nakamura Y, Aso E, Yashiro M, et al. Mortality among persons with a history of Kawasaki disease in Japan: can paediatricians safely discontinue follow-up of children with a history of the disease but without cardiac sequelae? Acta Paediatr. 2005;94:429–434.
  • Chang FY, Hwang B, Chen SJ, et al. Characteristics of Kawasaki disease in infants younger than six months of age. Pediatr Infect Dis J. 2006;25:241–244.
  • Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr. 1995;126:524–529.
  • Sonobe T, Kiyosawa N, Tsuchiya K, et al. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int. 2007;49:421–426.
  • Chen YC, Shen CT, Wang NK, et al. High Sensitivity C reactive protein (hs-CRP) in adolescent and young adult patients with history of Kawasaki disease. Acta Cardiol Sin. 2015;31:473–477.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.